Outcomes of Buccinator Treatment With Botulinum Toxin in Facial Synkinesis
- 17 May 2018
- journal article
- research article
- Published by SAGE Publications in JAMA Facial Plastic Surgery
- Vol. 20 (3) , 196-201
Abstract
Importance: The buccinator, despite being a prominent midface muscle, has been previously overlooked as a target in the treatment of facial synkinesis with botulinum toxin. Objective: To evaluate outcomes of patients treated with botulinum toxin to the buccinator muscle in the setting of facial synkinesis. Design, Setting, and Participants: Prospective cohort study of patients who underwent treatment for facial synkinesis with botulinum toxin over multiple treatment cycles during a 1-year period was carried out in a tertiary referral center. Interventions: Botulinum toxin treatment of facial musculature, including treatment cycles with and without buccinator injections. Main Outcomes and Measures: Subjective outcomes were evaluated using the Synkinesis Assessment Questionnaire (SAQ) prior to injection of botulinum toxin and 2 weeks after treatment. Outcomes of SAQ preinjection and postinjection scores were compared in patients who had at least 1 treatment cycle with and without buccinator injections. Subanalysis was performed on SAQ questions specific to buccinator function (facial tightness and lip movement). Results: Of 84 patients who received botulinum toxin injections for facial synkinesis, 33 received injections into the buccinator muscle. Of the 33, 23 met inclusion criteria (19 [82.6%] women; mean [SD] age, 46 [10] years). These patients presented for 82 treatment visits, of which 44 (53.6%) involved buccinator injections and 38 (46.4%) were without buccinator injections. The most common etiology of facial paralysis included vestibular schwannoma (10 [43.5%] participants) and Bell Palsy (9 [39.1%] participants). All patients had improved posttreatment SAQ scores compared with prebotulinum scores regardless of buccinator treatment. Compared with treatment cycles in which the buccinator was not addressed, buccinator injections resulted in lower total postinjection SAQ scores (45.9; 95% CI, 38.8–46.8; vs 42.8; 95% CI, 41.3–50.4; P = .43) and greater differences in prebotox and postbotox injection outcomes (18; 95% CI, 16.2–21.8; vs 19; 95% CI, 14.2–21.8; P = .73). Subanalysis of buccinator-specific scores revealed significantly improved postbotox injection scores with the addition of buccinator injections (5.7; 95% CI, 5.0–6.4; vs 4.1; 95% CI, 3.7–4.6; P = .004) and this corresponded to greater differences between prebotulinum and postbotulinum injection scores (3.3; 95% CI, 2.7–3.9; vs 2.0; 95% CI, 1.4–2.6; P = .02). The duration of botulinum toxin effect was similar both with and without buccinator treatment (66.8; 95% CI, 61.7–69.6; vs 65.7; 95% CI, 62.5–71.1; P = .72). Conclusions and Relevance: The buccinator is a symptomatic muscle in the facial synkinesis population. Treatment with botulinum toxin is safe, effective and significantly improves patient symptoms. Level of Evidence: 3 .Keywords
This publication has 20 references indexed in Scilit:
- Botulinum Toxin in the Treatment of Facial ParalysisFacial Plastic Surgery Clinics of North America, 2016
- ReOphthalmic Plastic & Reconstructive Surgery, 2016
- Facial Nerve Grading InstrumentsPlastic and Reconstructive Surgery, 2015
- Botulinum toxin injection of both sides of the face to treat post-paralytic facial synkinesisJournal of Plastic, Reconstructive & Aesthetic Surgery, 2013
- Botulinum toxin in the treatment of facial synkinesis and hyperkinesisThe Laryngoscope, 2012
- Management of SynkinesisFacial Plastic Surgery, 2008
- Validation of the Synkinesis Assessment QuestionnaireThe Laryngoscope, 2007
- Automated Facial Image AnalysisAnnals of Plastic Surgery, 2007
- Patterns of Facial Nerve SynkinesisThe Laryngoscope, 1996
- Botulinum Toxin Treatment in Patients with Facial Synkinesis1994